STUDY OF ANTIDEPRESSANTS IN PARKINSON'S DIS

抗抑郁药治疗帕金森病的研究

• 批准号: 7376965
• 负责人: LISA M. SHULMAN
• 金额: $ 0.1万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376965
• 关键词: STUDY; ANTIDEPRESSANTS; PARKINSON; DIS; STUDY; ANTIDEPRESSANTS; PARKINSON; DIS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a twelve-week placebo controlled study of paroxetine and venlafaxine extended release. Paroxetine and venlafaxine are drugs that have been approved by the FDA and are available by prescriptions. Paroxetine and venlafaxine have been shown to be effective in treating depression in the general population. There is a 2 in 3 chance that a participant will receive active drug and a 1 in 3 chance that they will receive placebo. This will be decided randomly, like flipping a coin. This is a double blind study, so neither the participant nor the investigator will know if they are receiving placebo or active drug. Only the pharmacist dispensing the medication will know which study treatment each participant will receive.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。这是一项为期十二周的安慰剂对照研究，对帕罗西汀和文拉法辛的扩展释放。 Paroxetine和Venlafaxine是已获得FDA批准的药物，可通过处方获得。帕罗西汀和文拉法辛已被证明可有效治疗普通人群的抑郁症。参与者将获得活跃的药物和三分之一的机会，他们将获得安慰剂。这将随机决定，就像翻转硬币一样。这是一项双盲研究，因此参与者和研究人员都不知道他们是否接受了安慰剂或活跃药物。只有分配药物的药剂师才能知道每个参与者将接受哪种研究治疗。